<?xml version="1.0" encoding="UTF-8"?>
<drug type="biotech" created="2007-11-18" updated="2020-01-02">
  <drugbank-id primary="true">DB05321</drugbank-id>
  <name>PEG-uricase</name>
  <description>PEG-uricase, a polyethylene glycol ("PEG") conjugate of recombinant porcine uricase (urate oxidase), which breaks down the uric acid deposits is being studied in Phase III clinical trials for the treatment of severe, treatment-refractory gout in the United States in 2006.</description>
  <cas-number/>
  <unii/>
  <state>liquid</state>
  <groups>
    <group>investigational</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <ref-id>A3373</ref-id>
        <pubmed-id>17826865</pubmed-id>
        <citation>Sherman MR, Saifer MG, Perez-Ruiz F: PEG-uricase in the management of treatment-resistant gout and hyperuricemia. Adv Drug Deliv Rev. 2008 Jan 3;60(1):59-68. Epub 2007 Aug 14.</citation>
      </article>
      <article>
        <ref-id>A3374</ref-id>
        <pubmed-id>3289428</pubmed-id>
        <citation>Chua CC, Greenberg ML, Viau AT, Nucci M, Brenckman WD Jr, Hershfield MS: Use of polyethylene glycol-modified uricase (PEG-uricase) to treat hyperuricemia in a patient with non-Hodgkin lymphoma. Ann Intern Med. 1988 Jul 15;109(2):114-7.</citation>
      </article>
    </articles>
    <textbooks/>
    <links/>
    <attachments/>
  </general-references>
  <synthesis-reference/>
  <indication>Investigated for use/treatment in hyperuricemia.</indication>
  <pharmacodynamics/>
  <mechanism-of-action>PEG-uricase is a recombinant, PEGylated formulation of a modified porcine urate oxidase intended to dramatically lower the blood level of uric acid safely and continuously in patients who have not benefited from conventional therapeutic approaches. Urate oxidase is a hepatic enzyme present in almost all mammals – but not in humans – that lowers uric acid levels in the blood by converting uric acid into allantoin, a benign substance which is then easily excreted in the urine.&#13;
&#13;
</mechanism-of-action>
  <toxicity/>
  <metabolism/>
  <absorption/>
  <half-life/>
  <protein-binding/>
  <route-of-elimination/>
  <volume-of-distribution/>
  <clearance/>
  <classification>
    <description/>
    <direct-parent>Peptides</direct-parent>
    <kingdom>Organic Compounds</kingdom>
    <superclass>Organic Acids</superclass>
    <class>Carboxylic Acids and Derivatives</class>
    <subclass>Amino Acids, Peptides, and Analogues</subclass>
  </classification>
  <salts/>
  <synonyms/>
  <products/>
  <international-brands>
    <international-brand>
      <name>Puricase</name>
      <company/>
    </international-brand>
  </international-brands>
  <mixtures/>
  <packagers/>
  <manufacturers/>
  <prices/>
  <categories>
    <category>
      <category>Alcohols</category>
      <mesh-id>D000438</mesh-id>
    </category>
    <category>
      <category>Compounds used in a research, industrial, or household setting</category>
      <mesh-id>D020313</mesh-id>
    </category>
    <category>
      <category>Enzymes</category>
      <mesh-id>D004798</mesh-id>
    </category>
    <category>
      <category>Enzymes and Coenzymes</category>
      <mesh-id>D045762</mesh-id>
    </category>
    <category>
      <category>Enzymes, Immobilized</category>
      <mesh-id>D004800</mesh-id>
    </category>
    <category>
      <category>Ethylene Glycols</category>
      <mesh-id>D005026</mesh-id>
    </category>
    <category>
      <category>Glycols</category>
      <mesh-id>D006018</mesh-id>
    </category>
    <category>
      <category>Macromolecular Substances</category>
      <mesh-id>D046911</mesh-id>
    </category>
    <category>
      <category>Oxidoreductases</category>
      <mesh-id>D010088</mesh-id>
    </category>
    <category>
      <category>Pegylated agents</category>
      <mesh-id/>
    </category>
    <category>
      <category>Polymers</category>
      <mesh-id>D011108</mesh-id>
    </category>
  </categories>
  <affected-organisms/>
  <dosages/>
  <atc-codes/>
  <ahfs-codes/>
  <pdb-entries/>
  <patents/>
  <food-interactions/>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB00008</drugbank-id>
      <name>Peginterferon alfa-2a</name>
      <description>The therapeutic efficacy of PEG-uricase can be decreased when used in combination with Peginterferon alfa-2a.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00019</drugbank-id>
      <name>Pegfilgrastim</name>
      <description>The therapeutic efficacy of PEG-uricase can be decreased when used in combination with Pegfilgrastim.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00022</drugbank-id>
      <name>Peginterferon alfa-2b</name>
      <description>The therapeutic efficacy of PEG-uricase can be decreased when used in combination with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00059</drugbank-id>
      <name>Pegaspargase</name>
      <description>The therapeutic efficacy of PEG-uricase can be decreased when used in combination with Pegaspargase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00061</drugbank-id>
      <name>Pegademase</name>
      <description>The therapeutic efficacy of PEG-uricase can be decreased when used in combination with Pegademase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00082</drugbank-id>
      <name>Pegvisomant</name>
      <description>The therapeutic efficacy of PEG-uricase can be decreased when used in combination with Pegvisomant.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01839</drugbank-id>
      <name>Propylene glycol</name>
      <description>The therapeutic efficacy of PEG-uricase can be decreased when used in combination with Propylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03394</drugbank-id>
      <name>Heptaethylene glycol</name>
      <description>The therapeutic efficacy of PEG-uricase can be decreased when used in combination with Heptaethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04895</drugbank-id>
      <name>Pegaptanib</name>
      <description>The therapeutic efficacy of PEG-uricase can be decreased when used in combination with Pegaptanib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05202</drugbank-id>
      <name>Egaptivon pegol</name>
      <description>The therapeutic efficacy of PEG-uricase can be decreased when used in combination with Egaptivon pegol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05860</drugbank-id>
      <name>Peginterferon alfacon-1</name>
      <description>The therapeutic efficacy of Peginterferon alfacon-1 can be decreased when used in combination with PEG-uricase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06022</drugbank-id>
      <name>GlycoPEG-GCSF</name>
      <description>The therapeutic efficacy of GlycoPEG-GCSF can be decreased when used in combination with PEG-uricase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06293</drugbank-id>
      <name>Pegnivacogin</name>
      <description>The therapeutic efficacy of Pegnivacogin can be decreased when used in combination with PEG-uricase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06325</drugbank-id>
      <name>Pegpleranib</name>
      <description>The therapeutic efficacy of Pegpleranib can be decreased when used in combination with PEG-uricase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06611</drugbank-id>
      <name>Pegsunercept</name>
      <description>The therapeutic efficacy of Pegsunercept can be decreased when used in combination with PEG-uricase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06811</drugbank-id>
      <name>Polidocanol</name>
      <description>The therapeutic efficacy of Polidocanol can be decreased when used in combination with PEG-uricase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08894</drugbank-id>
      <name>Peginesatide</name>
      <description>The therapeutic efficacy of Peginesatide can be decreased when used in combination with PEG-uricase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08904</drugbank-id>
      <name>Certolizumab pegol</name>
      <description>The therapeutic efficacy of Certolizumab pegol can be decreased when used in combination with PEG-uricase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09107</drugbank-id>
      <name>Methoxy polyethylene glycol-epoetin beta</name>
      <description>The therapeutic efficacy of Methoxy polyethylene glycol-epoetin beta can be decreased when used in combination with PEG-uricase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09122</drugbank-id>
      <name>Peginterferon beta-1a</name>
      <description>The therapeutic efficacy of Peginterferon beta-1a can be decreased when used in combination with PEG-uricase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09208</drugbank-id>
      <name>Pegloticase</name>
      <description>The therapeutic efficacy of Pegloticase can be decreased when used in combination with PEG-uricase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09287</drugbank-id>
      <name>Polyethylene glycol</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with PEG-uricase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09329</drugbank-id>
      <name>Antihemophilic Factor (Recombinant), PEGylated</name>
      <description>The therapeutic efficacy of Antihemophilic Factor (Recombinant), PEGylated can be decreased when used in combination with PEG-uricase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11077</drugbank-id>
      <name>Polyethylene glycol 400</name>
      <description>The therapeutic efficacy of Polyethylene glycol 400 can be decreased when used in combination with PEG-uricase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11567</drugbank-id>
      <name>Insulin peglispro</name>
      <description>The therapeutic efficacy of Insulin peglispro can be decreased when used in combination with PEG-uricase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11661</drugbank-id>
      <name>Eptacog alfa pegol (activated)</name>
      <description>The therapeutic efficacy of Eptacog alfa pegol (activated) can be decreased when used in combination with PEG-uricase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11707</drugbank-id>
      <name>Olaptesed Pegol</name>
      <description>The therapeutic efficacy of Olaptesed Pegol can be decreased when used in combination with PEG-uricase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12258</drugbank-id>
      <name>Abicipar Pegol</name>
      <description>The therapeutic efficacy of Abicipar Pegol can be decreased when used in combination with PEG-uricase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12578</drugbank-id>
      <name>Lexaptepid Pegol</name>
      <description>The therapeutic efficacy of Lexaptepid Pegol can be decreased when used in combination with PEG-uricase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12814</drugbank-id>
      <name>Cepeginterferon alfa-2B</name>
      <description>The therapeutic efficacy of Cepeginterferon alfa-2B can be decreased when used in combination with PEG-uricase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12839</drugbank-id>
      <name>Pegvaliase</name>
      <description>The therapeutic efficacy of Pegvaliase can be decreased when used in combination with PEG-uricase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12842</drugbank-id>
      <name>Pegamotecan</name>
      <description>The therapeutic efficacy of Pegamotecan can be decreased when used in combination with PEG-uricase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13200</drugbank-id>
      <name>Lipegfilgrastim</name>
      <description>The therapeutic efficacy of Lipegfilgrastim can be decreased when used in combination with PEG-uricase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13933</drugbank-id>
      <name>Nonacog beta pegol</name>
      <description>The therapeutic efficacy of Nonacog beta pegol can be decreased when used in combination with PEG-uricase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14700</drugbank-id>
      <name>Damoctocog alfa pegol</name>
      <description>The therapeutic efficacy of Damoctocog alfa pegol can be decreased when used in combination with PEG-uricase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14712</drugbank-id>
      <name>Elapegademase</name>
      <description>The therapeutic efficacy of Elapegademase can be decreased when used in combination with PEG-uricase.</description>
    </drug-interaction>
  </drug-interactions>
  <sequences/>
  <experimental-properties/>
  <external-identifiers>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>347910080</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>PEG-uricase</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links/>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target>
      <id>BE0001313</id>
      <name>Uric acid degradation bifunctional protein</name>
      <organism>Bacillus sp. (strain TB-90)</organism>
      <actions/>
      <references>
        <articles/>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="Q45697" source="Swiss-Prot">
        <name>Uric acid degradation bifunctional protein</name>
        <general-function>Urate oxidase activity</general-function>
        <specific-function>Catalyzes two steps in the degradation of uric acid, i.e. the oxidation of uric acid to 5-hydroxyisourate (HIU) and the stereoselective decarboxylation of 2-oxo-4-hydroxy-4-carboxy-5-ureidoimidazoline (OHCU) to (S)-allantoin (By similarity).</specific-function>
        <gene-name>uao</gene-name>
        <locus/>
        <cellular-location/>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>6.58</theoretical-pi>
        <molecular-weight>57977.435</molecular-weight>
        <chromosome-location/>
        <organism ncbi-taxonomy-id="36824">Bacillus sp. (strain TB-90)</organism>
        <external-identifiers>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>AB048366</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>12082301</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>Q45697</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>PUCL_BACSB</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>4.1.1.97</synonym>
          <synonym>OHCU decarboxylase</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0002608|Uric acid degradation bifunctional protein
MMRLKQLNEMSASEFIHLLGGVFENSSWVAERAEPNRPYSSFQSLYNKMVEIVETASDNE
QLKLIQMHPHLGTNVKITDFSQEEQKHAGLNELTKDEQNHLILLNQKYKDKFGFPFVMAV
RGKIKQEIFRTIKERLQNNHQTEFKQALEEIKKIAMFRLQEIFREGENNSMTKHKERVMY
YGKGDVFAYRTYLKPLTGVRTIPESPFSGRDHILFGVNVKISVGGTKLLTSFTKGDNSLV
VATDSMKNFIQKHLASYTGTTIEGFLEYVATSFLKKYSHIEKISLIGEEIPFETTFAVKN
GNRAASELVFKKSRNEYATAYLNMVRNEDNTLNITEQQSGLAGLQLIKVSGNSFVGFIRD
EYTTLPEDSNRPLFVYLNIKWKYKNTEDSFGTNPENYVAAEQIRDIATSVFHETETLSIQ
HLIYLIGRRILERFPQLQEVYFESQNHTWDKIVEEIPESEGKVYTEPRPPYGFQCFTVTQ
EDLPHENILMFSDEPDHKGALK</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0002607|1509 bp
ATGATGCGATTAAAACAATTAAATGAAATGAGTGCTTCCGAATTTATCCATCTATTAGGA
GGAGTTTTTGAGAATTCATCATGGGTGGCCGAACGAGCAGAACCCAATCGCCCATACTCT
TCCTTTCAATCTCTATATAATAAAATGGTGGAGATTGTCGAAACCGCTTCGGATAACGAA
CAATTAAAATTAATTCAAATGCATCCGCATCTAGGCACCAACGTCAAAATAACCGATTTC
TCTCAAGAGGAACAGAAACATGCCGGATTAAATGAATTAACAAAAGATGAACAGAATCAT
CTCATTTTACTCAACCAAAAATACAAGGATAAATTTGGATTTCCATTTGTAATGGCCGTT
CGAGGAAAAATCAAACAAGAAATTTTTAGAACGATCAAAGAACGATTACAAAATAATCAT
CAAACGGAGTTTAAACAAGCATTGGAAGAAATTAAAAAAATCGCAATGTTTCGTTTGCAA
GAAATATTTCGTGAAGGAGAGAATAATTCGATGACCAAACACAAAGAAAGAGTGATGTAT
TATGGAAAAGGTGACGTATTTGCTTATCGCACCTATTTAAAACCACTTACTGGAGTTAGA
ACGATTCCTGAATCTCCATTTTCCGGTCGAGATCATATTCTTTTTGGAGTAAATGTAAAA
ATCTCAGTAGGAGGAACAAAATTGCTGACCTCCTTTACGAAAGGGGATAACAGCTTAGTC
GTTGCAACAGACTCGATGAAAAACTTTATACAAAAACATTTAGCTAGTTATACAGGAACA
ACGATAGAAGGTTTTTTAGAATATGTAGCTACTTCTTTTTTGAAGAAATATTCTCATATT
GAAAAGATTTCGTTGATAGGAGAGGAAATTCCCTTTGAAACAACTTTTGCAGTAAAGAAT
GGAAATAGAGCAGCTAGTGAGCTAGTATTTAAAAAATCACGAAATGAATATGCCACCGCT
TATTTGAATATGGTTCGTAATGAAGATAACACCCTAAACATTACTGAACAACAAAGCGGA
CTTGCTGGTCTTCAATTAATAAAAGTCAGCGGAAATTCCTTTGTCGGTTTTATTCGTGAC
GAATACACAACTCTTCCAGAGGATTCAAACCGCCCTCTATTTGTTTACTTAAACATCAAA
TGGAAGTACAAAAACACGGAAGACTCATTTGGAACGAATCCAGAAAATTATGTTGCAGCT
GAACAAATTCGCGACATCGCCACTTCCGTATTTCATGAAACCGAGACGCTTTCCATCCAA
CATTTAATTTATTTAATCGGCCGCAGAATATTAGAAAGATTCCCTCAACTTCAAGAAGTT
TACTTCGAATCTCAAAATCATACATGGGATAAAATAGTGGAGGAAATTCCTGAATCAGAA
GGGAAAGTATATACAGAACCGCGACCGCCATATGGATTTCAATGCTTTACTGTCACCCAA
GAAGACTTGCCACACGAAAACATTCTTATGTTCTCTGATGAACCCGATCATAAAGGAGCA
CTTAAATGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF01014</identifier>
            <name>Uricase</name>
          </pfam>
          <pfam>
            <identifier>PF09349</identifier>
            <name>OHCU_decarbox</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>function</category>
            <description>carboxy-lyase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>urate oxidase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>allantoin biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>purine nucleobase metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>urate catabolic process</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
  </targets>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>